Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Randomized, Double-blind, Placebo Controlled, Multi-center 12-week Study With an Additional 40-week Follow-up Assessment of Efficacy, Safety and Tolerability of M1095 in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

NCT03384745 is registered in ClinicalTrials.gov with Bond Avillion 2 Development LP as lead sponsor.

NCT NCT03384745
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03384745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Randomized, Double-blind, Placebo Controlled, Multi-center 12-week Study With an Additional 40-week Follow-up Assessment of Efficacy, Safety and Tolerability of M1095 in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Lead sponsor
Bond Avillion 2 Development LP
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2018
Completion date
March 26, 2020
Enrollment
313 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis